tjlpa Profile

Tom Lamb
Join Date:
2008-09-08
About
I am a lawyer in Wilmington, North Carolina, with a national litigation practice and I have been recognized by other lawyers (that is, my peers) as practicing law at the highest level of professional experience -- which is indicated by me having an A-V rating (highest classification) peer-review rating from the Martindale-Hubbell Lawyer Directory.
I started the Law Offices of Thomas J. Lamb in 1996 after working at one of the nation’s largest plaintiff law firms, Ness Motley Loadholt Richardson & Poole, in Charleston, South Carolina. Prior to that, I worked on the other side of the fence at a defense firm, Keesal Young & Logan, in Long Beach, California.
I have had some of my articles published online by Reuters, Fox News, and other media sites. Over the years I been interviewed by The National Law Journal, CBS Nightly News, The New York Times, and Forbes, as well as by other journalists working in print and on TV.
I was first licensed to practice law in California (1988). I was admitted thereafter to practice in the District of Columbia (1990) and in North Carolina in (1992).
I went to law school at George Washington University, in Washington, D.C.
I did my undergraduate work at the College of William & Mary, in Williamsburg, Virginia.
I enjoy living near the coast with my wife and family, which in large part is why my law firm is located in Wilmington, North Carolina, close to Wrightsville Beach.
If you, relatives, or friends have a possible personal injury or wrongful death case, please feel free to contact me about your case or use one of our online Case Evaluation forms, where you will find that (unlike many legal web sites) we use a specific questionnaire form for each different type of case in order to make clear the type of facts and information that we need to effectively evaluate your potential case. I am usually able to reply no later than the next business day to any Case Evaluation form you submit to us.
http://www.lamblawoffice.com/Evaluation-Menu.html
Thanks for reading. Have a nice day.
I started the Law Offices of Thomas J. Lamb in 1996 after working at one of the nation’s largest plaintiff law firms, Ness Motley Loadholt Richardson & Poole, in Charleston, South Carolina. Prior to that, I worked on the other side of the fence at a defense firm, Keesal Young & Logan, in Long Beach, California.
I have had some of my articles published online by Reuters, Fox News, and other media sites. Over the years I been interviewed by The National Law Journal, CBS Nightly News, The New York Times, and Forbes, as well as by other journalists working in print and on TV.
I was first licensed to practice law in California (1988). I was admitted thereafter to practice in the District of Columbia (1990) and in North Carolina in (1992).
I went to law school at George Washington University, in Washington, D.C.
I did my undergraduate work at the College of William & Mary, in Williamsburg, Virginia.
I enjoy living near the coast with my wife and family, which in large part is why my law firm is located in Wilmington, North Carolina, close to Wrightsville Beach.
If you, relatives, or friends have a possible personal injury or wrongful death case, please feel free to contact me about your case or use one of our online Case Evaluation forms, where you will find that (unlike many legal web sites) we use a specific questionnaire form for each different type of case in order to make clear the type of facts and information that we need to effectively evaluate your potential case. I am usually able to reply no later than the next business day to any Case Evaluation form you submit to us.
http://www.lamblawoffice.com/Evaluation-Menu.html
Thanks for reading. Have a nice day.
Blogs Owned
Site provides developing information about prescription drug side effects as well as up-to-date news.. from the legal, medical, FDA, and pharmaceutical sectors.
Other Tags: drug-injury, side-effects, medications, FDA, pharmaceutical
2 - AsbestosHUB
Site provides developing information about various asbestos-related topics, ranging from new.. treatments for mesothelioma to recent asbestos lawsuits, settlements, and trial verdicts.
Other Tags: asbestos, mesothelioma, asbestosis, medical-treatment, legal-cases
Latest Blog Posts
- Asbestos ban to be announced by federal government next weekThe federal government plans to announce a comprehensive ban on asbestos in Canada next week, CBC News has learned. The country currently allows imports of construction products and automotive parts that contain the toxic fibre, even though Canada no...
- Canada should stop importing deadly asbestos, labour group saysThe Canadian Labour Congress is calling for a ban on asbestos. Exposure to asbestos — a fibrous mineral used in building and construction — is the leading cause of workplace-related death in Canada. Canada stopped exporting asbestos in 2011, and...
- Treatments to prolong life for mesothelioma patients closeron Nov 15, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma mesothelioma treatmentResearchers have uncovered a strange way that asbestos-related tumours grow, which could pave the way towards better treatments. The scientists at Adelaide’s Flinders University have found that malignant mesothelioma tumours are able to transfo...
- New Paradigms in the Treatment of Mesothelioma and NSCLC: An Overview by Fred Hirschon Nov 11, 2016 in Medicine asbestos-cancer asbestos-related disease malignant mesothelioma mesothelioma treatmentDr. Haffizulla: Welcome to PracticeUpdate. I’m Dr. Farzanna Haffizulla. Joining me today is Dr. Fred Hirsch, CEO of the International Association for the Study of Lung Cancer, and Professor of Medicine at the University of Colorado in Denver. Dr.
- Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesotheliomaon Nov 10, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma pleural-mesotheliomaMalignant pleural mesothelioma shows marked cytoarchitectural diversity. The aim of the study was to evaluate how morphological phenotype impacted upon overall survival. 191 cases of malignant pleural mesothelioma with available follow-up were identi...
- Residual fibre lung burden among patients with pleural mesothelioma who have been occupationally exposed to asbestosObjectives To evaluate the lungs asbestos fibres concentration in participants with malignant pleural mesothelioma (MPM) who have been occupationally exposed. Methods The lung samples were obtained from pleuropneumonectomies or autopsies of 271 m...
- Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapyPemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. Recently, we emphasi...
- Arginine Deprivation for Malignant Pleural MesotheliomaArginine deprivation is a novel anticancer strategy in argininosuccinate synthetase 1 (ASS1)–negative tumors. In a multicenter, phase II trial, immunohistochemistry identified 68 patients with ASS1 deficiency among 201 patients with malignant pleur...
- Scientists discover new option for treating malignant pleural mesotheliomaon Oct 24, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma mesothelioma treatmentResearchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. For the first time in the world, they were able to show in a preclinical study, both...
- Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature reviewon Oct 19, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma pleural-mesotheliomaAbstract Background Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5–10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or...
- Asbestos-related cancer costs Canadians billionsA first-ever estimate of the toll of asbestos-related cancers on society pegs the cost of new cases at $1.7-billion per year in Canada, and notes that is likely an under-estimate. The economic burden of lung cancer and mesothelioma from work-related...
- Lawyers For Plaintiffs And Drug Company Merck Make Their Arguments To Third Circuit Appeals Court In Fosamax - Femur Fracture LitigationOne Of The Legal Issues Is Whether Merck Could Have And Should Have Strengthened The Drug Label Warnings About This Apparent Side Effect, Or Not (Posted by Tom Lamb at DrugInjuryWatch.com) The title of out last article about the Fosamax drug injury l...
- Eliquis, Savaysa, And Xarelto: New Blood Thinner Drugs Feared By Many Doctors Because No Antidote Is Available When NeededSome Recent Articles Point Out the Real Problems And Consequences Of Major Bleeding Events Involving Eliquis, Savaysa, And Xarelto (Posted by Tom Lamb at DrugInjuryWatch.com) As many of you know from direct-to-consumer advertising on television, ther...
- FDA Adds Ketoacidosis Warnings To Diabetes Drugs Invokana, Farxiga, And Jardiance As Well As Other SGLT2 Inhibitorson Dec 8, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Health Canada News Side Effect: Blood-acid Disorders (acidosis, ketoacidosis, ketosis) Side Effect: Kidney Injury (acute renal failure, kidney transplant) acute renal failure diabetes drugs drug injury drug label changes Farxiga FDA Forxiga Glyxambi Health Canada increased risks Invokamet Invokana ketoacidosis kidney failure kidney problems lawsuits safety issues SGLT2 inhibitor side effects Sodium Glucose Cotransporter 2 Inhibitorsacuters Synjardy Xigduo XRThis Follows October 2015 Safety Alert By Health Canada Concerning Increased Risks Of Kidney Problems (Posted by Tom Lamb at DrugInjuryWatch.com) In December 2015 the FDA issued a Drug Safety Communication concerning the risk of ketoacidosis, a serio...
- Is Eliquis Safer Than Xarelto And Pradaxa If It Causes Fewer Dangerous Major Bleeding EventsPerhaps, But Neither Eliquis Nor Xarelto Have Any Specific Reversal Agent To Stop An Acute Bleed Once It Starts; Only Pradaxa Does (Posted by Tom Lamb at DrugInjuryWatch.com) During the American Heart Association 2015 Scientific Sessions in Orlando,...
- Zofran: MDL No. 2657 Pending In Massachusetts With Judge Dennis Saylor Presiding Over These Drug Injury Birth Defects LawsuitsWomen Who Used Zofran Had Babies With Cleft Palate / Cleft Lip, Various Types Of Heart-Related Problems, And Other Congenital Malformations (Posted by Tom Lamb at DrugInjuryWatch.com) In July 2015 the drug company GlaxoSmithKline (GSK) filed a motion...
- Hepatitis C Drugs Viekira Pak And Technivie Require Warnings Label Changes Due To Liver Injury ReportsFDA Says The Timing Of Liver Injury Suggests That These Are Side Effects, Especially In Patients With Advanced Cirrhosis (Posted by Tom Lamb at DrugInjuryWatch.com) Viekira Pak and Technivie are relatively new drugs used to treat chronic hepatitis C.
- Bayer's Corporate Reports About Their YAZ / Yasmin Settlement Program Show Progress Continues To Be Made, Albeit At A Slow PaceFirst Lawsuits In The YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral Drug Injury Litigation Were Filed In 2009, With Thousands Of Cases Still Pending (Posted by Tom Lamb at DrugInjuryWatch.com) The most recent Bayer information about the YAZ / Yasm...
- Xarelto, Savaysa, Pradaxa, And Eliquis: Safety Secondary To Ease Of Use Is "A Major Wrong Turn" Says Drug Watchdog Groupon Oct 9, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Side Effect: Bleeding Events (hemorrhage, overanticoagulation) adverse drug reactions anticoagulants antiplatelet agents aspirin clopidogrel deaths drug injury Eliquis FDA gastrointestinal bleeds intracranial bleeding nonsteroidal anti-inflammatory drugs NSAIDS platelet inhibitors Plavix Pradaxa Savaysa side effects XareltoThis New Generation Of Oral Anticoagulants Has Bleeding-Related Adverse Reactions Including Gastrointestinal And Intracranial Bleeds (Posted by Tom Lamb at DrugInjuryWatch.com) The ISMP QuarterWatch published on September 23, 2015 includes an examina...
- New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With "joint pain that can be severe and disabling"on Aug 28, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Side Effect: Joint Problems (arthralgia, joint pain, arthritis) arthralgia diabetes drugs dipeptidyl peptidase-4 inhibitors DPP-4 drug class drug injury drug safety FDA warnings Januvia joint pains label changes Nesina Onglyza side effects TradjentaLabel Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced that it has found indications of a ne...